Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease

Summary

This study is designed as a masked, two center, randomized, placebo-controlled pilot study to evaluate the safety and efficacy of nasal and oral inhalation of 75 mg aztreonam in subjects with CF and lung infection due to PA. The study will involve two sites: Virginia Commonwealth University Medical Center (VCU) and Eastern Virginia Medical School (EVMS). Potential subjects will be identified in each site's CF clinic.

Timeline

Start

2017-01

Primary completion

2019-09-19

Completion

2019-09-19

Drugs

Indications